Anales de la RANM

250 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PROTONTERAPIA CLÍNICA 2030 Calvo Manuel FA, et al. An RANM. 2023;140(03): 233 - 251 21. Laughlin BS, Thorpe CS, DeWees TA et al. Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Inter- mediate-Risk Adenocarcinoma of the Prosta- te: PCG GU003. Adv Radiat Oncol. 2022 Dec 9;8(3):101142. doi: 10.1016/j.adro.2022.101142. PMID: 36896215; PMCID: PMC9991536. 22. Lin SH, Hobbs BP, Verma V et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for lo- cally advanced esophageal cancer. J ClinOn- col. 2020; 38(14): 1569-1579. doi: 10.1200/ JCO.19.02503 23. Xi M, Xu C, Liao Z et al. Comparative Outco- mes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modula- ted Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):667- 676. doi: 10.1016/j.ijrobp.2017.06.2450. Epub 2017 Jun 27. PMID: 29280461. 24. Garant A, Spears G, Routman D et al. A Multi- Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Thera- py for Esophageal Cancer. Pract Radiat Oncol. 2021 Jul-Aug;11(4):e415-e425. doi: 10.1016/j. prro.2021.01.004. Epub 2021 Jan 21. PMID: 33486102. 25. Nonaka T, Kawashiro S, Ishikawa H et al; Esophageal Cancer Practice Guidelines Prepara- tion Committee. Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a syste- matic review. Esophagus. 2023; 20(4): 605-616. doi: 10.1007/s10388-023-01015-x . 26. Chen Y, Luo H, Liu R et al. Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis. Radiat Oncol. 2023; 18(1): 86. doi: 10.1186/s13014-023-02264-x 27. Spigel DR, Faivre-Finn C, Gray JE et al. Five- Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiothera- py in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2. Erra- tum in: J Clin Oncol. 2022 Jun 10;40(17):1965. PMID: 35108059; PMCID: PMC9015199. 28. Mutter RW, Choi JI, Jimenez RB et al. Proton therapy for breast cancer: a consensus state- ment from the particle therapy cooperative group breast cancer subcommittee. Int J Radiat Oncol Biol Phys. 2021; 111(2): 337-359. doi: 10.1016/j.ijrobp.2021.05.110 29. Gao RW, Mullikin TC, Aziz KA et al. Post- mastectomy Intensity Modulated Proton The- rapy: 5-Year Oncologic and Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2023 Nov 15;117(4):846-856. doi: 10.1016/j.ijro- bp.2023.05.036. Epub 2023 May 26. PMID: 37244627. 30. Mutter RW, Jethwa KR, Gonuguntla K et al. 3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and pa- tient reported outcomes of a novel regimen. Ra- diat Oncol. 2019 Nov 21;14(1):211. doi: 10.1186/ s13014-019-1417-7. PMID: 31752934; PMCID: PMC6873533. 31. Mutter RW, Giri S, Fruth BF et al. Conventio- nal versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial. Lancet Oncol. 2023; 24(10): 1083-1093. doi: 10.1016/S1470- 2045(23)00388-1 32. Jethwa KR, Tryggestad EJ, Whitaker TJ et al. Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, do- simetric analysis, acute treatment-related ad- verse events, and patient-reported outcomes. Adv Radiat Oncol. 2018; 13(3): 314-321. doi: 10.1016/j.adro.2018.04.003 33. Yamazaki H, Shibuya K, Kimoto T et al. Pro- ton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-insti- tutional patients' registration database, Pro- ton-Net. Clin Transl Radiat Oncol. 2023; 41: 100634. doi: 10.1016/j. ctro.2023.100634 34. Scorsetti M, Mancosu P, Navarria P et al. Ste- reotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of ad- vanced techniques with modulated photons and protons. Strahlenther Onkol. 2011; 187(4): 238-244. doi: 10.1007/s00066-011-2207-9 35. Fok M, Toh S, Easow J et al. Proton beam the- rapy in rectal cancer: a systematic review and meta-analysis. Surg Oncol. 2021; 38: 101638. doi: 10.1016/j.suronc.2021.101638 36. Pedone C, Sorcini B, Staff C et al. Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal can- cer (PRORECT): Initial dosimetric experien- ce. Clin Transl Radiat Oncol. 2022; 39: 100562. doi: 10.1016/j.ctro.2022.100562 37. Takaoka EI, Miyazaki J, Ishikawa H et al. Long-term single-institute experience with trimodal bladder-preserving therapy with pro- ton beam therapy for muscle-invasive bladder cancer. J Clin Oncol. 2017; 47(1): 67-73. doi: 10.1093/jjco/hyw151 38. Berlin E, Yegya-Raman N, Garver E, Li T, Lin LL, Taunk NK. Acute and long-term toxicity of whole pelvis proton radiation therapy for defi- nitive or adjuvant management of gynecologic cancers. Gynecol Oncol. 2023; 172: 92-97. doi: 10.1016/j.ygyno.2023.03.003 39. Dabaja BS, Hoppe BS, Plastaras JP et al. Pro- ton therapy for adults with mediastinal lym- phomas: the International Lymphoma Ra- diation Oncology Group guidelines. Blood. 2018; 132(16): 1635-1646. doi: 10.1182/ blood-2018-03-837633 40. Yang JT, Wijetunga NA, Pentsova E et al. Rando- mized phase II trial of proton craniospinal irra- diation versus photon involved-field radiothera- py for patients with solid tumor leptomeningeal metastasis. J Clin Oncol. 2022; 40(33): 3858- 3867. doi: 10.1200/JCO.22.01148 41. Verma V, Mishra MD, Mehta MP. A systema- tic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016; 122 (10): 1483-1501. doi: 10.1002/cncr.29882